Patents
Patents for C07D 241 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings (18,673)
05/2008
05/02/2008WO2008050117A1 Benzoyl amino heterocyclyl compounds as glucokinase (glk) activators
05/02/2008WO2008049806A1 Piperidine or piperazine substituted tetrahydro-naphthalene-1-carboxylic acid mtp inhibiting compounds
05/02/2008WO2008019971A3 Arylpiperazine derivatives and uses thereof
05/02/2008CA2667316A1 Benzoyl amino heterocyclyl compounds as glucokinase (glk) activators
05/02/2008CA2664141A1 Piperidine or piperazine substituted tetrahydro-naphthalene-1-carboxylic acid mtp inhibiting compounds
05/01/2008US20080103302 Novel acyl urea, thiourea, carbamate, thiocarbamate and related compounds are provided which are effective in inhibiting the cytokine-mediated inflammatory response in cultured cells, in ameliorating bone destruction in an animal model of arthritis and in lowering blood glucose levels in animal or cancer
05/01/2008US20080103300 Preparation of quinoxaline compounds
05/01/2008US20080103148 Preventing ventilator induced pneumonia; utilizing compounds having longer half life on mucosal surfaces
05/01/2008US20080103061 Functionalized compositions for improved immobilization
05/01/2008US20080102311 Material for organic electroluminescent element and organic electroluminescent element employing the same
05/01/2008US20080102031 4-[(4-N,N-diethylaminocarbonyl)phenyl]-spiro[2H,1-benzopyran-2,4'-piperidine; ligands of delta opioid receptor; analgesic, anxiolitic, antidepressant, analgesic; gastrointestinal disorders, neurodegenerative diseases; side effect reduction
04/2008
04/30/2008CN101168530A 1,4-dioxoquinoxaline formaldehyde dihydrazone with weed control activity and its preparation method and application
04/30/2008CN100384423C Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
04/29/2008US7365194 Dimer of phenazine-1-carboxylic acid and to the process of preparation thereof
04/29/2008US7365076 for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders
04/29/2008US7365075 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors; potentiation; diabetes and obesity; 2-(4-{4-[1-(6-chloro-pyridin-3-yl)cyclopropylmethyl]-2-(R)-methyl-piperazine-1-sulfonyl}phenyl)-1,1,1-trifluoro-propan-2-ol
04/29/2008US7365074 Pyridazine, pyrimidine and pyrazine ethyne compounds
04/29/2008US7365072 Inhibitors of p38
04/29/2008US7365070 Such as N-{2-[2-(5-Bromo-2-methoxy-phenyl)-ethyl]-3-fluoro-benzoyl}-N'-butyl-guanidine; involuntary weight loss disorders
04/29/2008US7365068 Hepatitis C virus infections; -(3-cyclopropyl-4-(pentyloxy)phenyl)-3-nicotinoylthiourea;methyl 2-oxo-2-(5-((3-(4-(pentyloxy)-3-(trifluoromethyl)phenyl)thioureido)carbonyl)pyridin-2-ylamino)acetate
04/29/2008US7365065 Antigonadotrophins; Breast and prostate cancer, endometriosis and benign prostate hyperplasia; regulation of fertility; in-vitro fertilisation; oral administration; inexpensive; 3-Amino-4-chloro-N-[4-chloro-5-(2,3-dihydro-benzo[1,4]oxazine-4-carbonyl)-thiophen-3-ylmethyl]-N-methyl-benzenesulfonamide
04/29/2008CA2245484C Novel urea derivatives
04/29/2008CA2209465C Process for preparing 3-alkoxy-5-alkylpyrazin-2-amines
04/24/2008WO2008047589A1 Quinoxaline derivative, and light-emitting element and light-emitting device using quinoxaline derivative
04/24/2008US20080096896 Cyclic Amide & Ester Pyrazinoylganidine Sodium Channel Blockers
04/24/2008US20080096894 Anti-Bacterial Compounds
04/24/2008US20080096892 C-Kit Modulators And Methods Of Use
04/24/2008US20080096875 Hepatitis C virus infection; thiourea-substituted dibenzofuran, fluorene, or carbazole compounds
04/24/2008US20080096873 New compounds
04/24/2008US20080096869 Adamantyl acetamides as 11-beta hydroxysteroid dehydrogenase inhibitors
04/24/2008US20080095842 Rapidly Disintegrating Taste Masked Compositions and a Process for Its Preparations
04/23/2008EP1912954A2 Novel cysteine protease inhibitors and their therapeutic applications
04/23/2008EP1303483B1 Novel thiourea derivatives and the pharmaceutical compositions containing the same
04/23/2008CN101166722A Process for preparing 3,3-disubstituted oxindoles and thio-oxindoles
04/22/2008US7361679 Integrin VLA-4 ( alpha 4 beta 1) and/or integrin LPAM-1 ( alpha 4 beta 7) antagonists, cell adhesion inhibitor; bioavailability, oral administration;treating inflammatory diseases; e.g. 3-[2-(2,6-dichlorobenzoylamino)pyrid-5-yl]-2-{3-[(2,2-dimethylpropionyl)isobutylamino]-4-methoxyphenyl}propionic acid
04/22/2008US7361666 Ligands for cellular receptors, including opiate receptors; side effect reduction; base structure is a saturated nitrogen-containing ring substituted with a tertiary amide that is N-substituted with an arylalkyl group
04/22/2008US7361648 1-(4-{ethyl-[2-(4-methanesulfonylphenyl)-1-methylethyl]amino}butyl)-4-methanesulfonyl-[1,4]diazepan-2-one; repiratory system disorders: asthma and chronic obstructive pulmonary disease; nervous system, muscular,urogenital, gastrointestinal disorders; antiallergens; side effect reduction
04/17/2008WO2008044767A1 Aromatic amine derivative and use thereof
04/17/2008WO2008043775A1 Substituted pyrazinone derivatives for use as a medicine
04/17/2008WO2008022164A3 Pyrazine compounds, their use and methods of preparation
04/17/2008WO2008022046A3 Dicer substrate rna peptide conjugates and methods for rna therapeutics
04/17/2008US20080091012 Exhibits a broad emission spectrum when used for a light-emitting element; white light emission with excellent color rendering
04/17/2008US20080090840 Heterocyclic GPR40 Modulators
04/17/2008US20080090838 N-Hydroxyamide Derivatives and Use Thereof
04/17/2008US20080090837 Biaryls useful as modulators of ion channels
04/17/2008US20080090822 Piperazine Derivatives As Glyt 1 Inhibitors
04/17/2008US20080090785 Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents
04/17/2008CA2659923A1 Substituted pyrazinone derivatives for use as a medicine
04/16/2008EP1910277A1 Quadratic acid derivatives in the form of a protein kinase inhibitors
04/16/2008EP1909797A2 Dipiperazinyl ketones and related analogues
04/16/2008EP1426356B1 Intermediate compounds for the preparation of mirtazapine and the production methods thereof
04/16/2008CN101163711A Organometallic complex, light-emitting element using it, light-emitting device and electronic device
04/16/2008CN101163699A Methods for synthesis of dicarbamate compounds and intermediates in the formation thereof
04/16/2008CN101163662A Phenylacetylene derivatives having mglur5 receptor affinity
04/16/2008CN101161641A Tricyclic steroid hormone nuclear receptor modulators
04/15/2008US7358365 Process for the controlled increase in the molecular weight of polyethylenes
04/15/2008US7358359 Antibacterial agents
04/15/2008US7358239 Treating impaired fundic relaxation; [1(R),[A-(3 alpha ,4 alpha )]]-1-[1-[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]-3-methoxy-4-piperidinyl]-2(1H)-pyrimidinone
04/15/2008CA2410303C Beta-amino acid nitrile derivatives
04/10/2008WO2008043087A2 Bicyclic nitrogen-containing heterocyclic compounds for use as stearoyl coa desaturase inhibitors
04/10/2008WO2008040934A1 Hdac inhibitors
04/10/2008WO2008040651A1 3-pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as hdl-cholesterol raising agents
04/10/2008WO2008040649A2 Pyrazine-2-carboxamide derivatives as cb2 receptor modulators
04/10/2008WO2008003702A3 Fused bicyclic compounds interacting with the histamine h4 receptor
04/10/2008WO2007144652A3 Parp inhibitors
04/10/2008US20080085905 Pyrazine-2-carboxamide derivatives
04/10/2008US20080085900 Sulfonylguanidine compounds and pharmaceutical uses thereof
04/10/2008US20080085893 N-Hydroxy (2S)-2-hydroxy phenyl or heteroaryl sulfonamide derivatives; for example, N-Hydroxy (2S)-2-hydroxy-3-{N-[4-(4- chlorophenoxy)phenyl], N- methanesulfonylamino}propionamide; for treating disorders related to matrix metalloproteases, particularly useful for treating strokes;
04/10/2008US20080085890 Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3 (2H)-isoquinolones and methods of use thereof
04/10/2008CA2665428A1 Hdac inhibitors
04/10/2008CA2664621A1 Pyrazine-2-carboxamide derivatives
04/10/2008CA2664119A1 3-pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as hdl-cholesterol raising agents
04/09/2008EP1907387A1 An oxime derivative and preparations thereof
04/09/2008EP1906964A1 Piperazinone derivatives useful as histamine h3 receptor antagonists and/or inverse agonists
04/09/2008EP1309565B1 Heterocyclic mutilin esters and their use as antibacterials
04/08/2008US7355045 Isotopically enriched N-substituted piperazine acetic acids and methods for the preparation thereof
04/08/2008US7354946 Biarylurea derivatives
04/08/2008US7354923 Piperazine melanocortin-specific compounds
04/08/2008US7354922 Bridged ring NK1 antagonists
04/03/2008WO2007135131A9 Substituted pyrazinone derivatives for use as a medicine
04/03/2008US20080081818 New Piperazine Compound and Use Thereof as a HCV Polymerase Inhibitor
04/03/2008US20080081813 Lipid Lowering Biphenylcarboxamides
04/03/2008US20080081812 and inverse agonist; 2-(5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazol-3-yl)-5-(pyridin-4-yl)-1,3,4-oxadiazole; obesity and obesity-related metabolic disorders
04/03/2008US20080079354 Quinoxaline Derivative, And Light Emitting Element, Light Emitting Device, And Electronic Device Using the Quinoxaline Derivative
04/03/2008US20080079353 Quinoxaline Derivative, And Light-Emitting Device, Electronic Device Using The Quinoxaline Derivative
04/02/2008CN101155789A 1h-quinaz0line-2,4-diones and their use as ampa-receptor ligands
04/02/2008CN101155588A Inhibitors of akt activity
04/02/2008CN101153026A Quinoxaline derivative, and light emitting element, light emitting device, and electronic device using the quinoxaline derivative
04/02/2008CN100378063C Novel compounds and medicinal use thereof
04/01/2008US7351825 4-[5-((1S,2R)-1-Carboxy-2-phenyl-cyclopropylsulfamoyl)-thiophen-2-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester; aggrecanase and matrix metalloproteinase (with zinc in the catalytic active center) (MMP) inhibitor; antiarthritic agent: osteoarthritis, rheumatoid arthritis
04/01/2008US7351709 Estrogen receptor ligands
04/01/2008US7351703 Which modulate the endogenous production of cyclic guanosine monophosphate (cGMP); for therapy and prophylaxis of cardiovascular disorders such as high blood pressure, angina pectoris, cardiac insufficency, thromboses, and/or atherosclerosis
03/2008
03/27/2008WO2008008431A3 Heteroaryl sulfonamides and ccr2/ccr9
03/27/2008US20080076918 Quinoxaline compounds
03/27/2008US20080076782 Sodium channel blockers
03/27/2008US20080076781 Pseudobase benzo[c]phenanthridines with improved efficacy, stability, and safety
03/27/2008US20080076775 3-(2-alkoxycarbonyl-3-indolyl)-3-oxo-propionic acid ester or propionamide intermediates: methyl 3-[6-fluoro-2-(methoxycarbonyl)-1-methyl-1H-indol-3-yl]-3-oxopropanoate; peripheral neuropathy, Parkinson's disease, Alzheimer's disease
03/27/2008US20080076769 Norvaline Derivative and Method for Preparation Thereof
03/27/2008US20080076762 Novel 4-Aminopiperidine Derivatives
03/26/2008EP1902028A2 Histamine h3 receptor antagonists
1 ... 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 ... 187